InvestorsHub Logo
Followers 1171
Posts 34538
Boards Moderated 0
Alias Born 03/26/2007

Re: None

Tuesday, 05/11/2021 9:52:01 PM

Tuesday, May 11, 2021 9:52:01 PM

Post# of 13742
NFF CANCER RESEARCH (City Of Hope)...
https://www.nfcr.org/blog/scorpion-venom-the-newest-treatment-for-a-deadly-cancer/

Scorpion Venom: The Newest Treatment for a Deadly Cancer

Each year as the ground begins to thaw, people across America celebrate National Brain Cancer Awareness Month. While all types of brain cancers are in the spotlight during the month of May, glioblastoma multiforme (referred to simply as GBM) is often at the forefront of everyone’s mind. With only a 5% five-year survival rate, GBM is the deadliest type of cancer. It is a fast-acting disease that warrants little time for trials and research to be conducted. As a result, GBM survival rates have not improved in any meaningful way over the last 30 years. In a recent study, however, researchers have identified the first chimeric antigen receptor (CAR) T cell therapy that can target brain tumor cells. The newly identified piece to the puzzle? Scorpion venom.

Much like a scorpion uses toxin components to target and kill its prey, the research team at City of Hope are using it to direct T cells to target the cancerous cells. Using a component of scorpion venom called chlorotoxin (CLTX), these researchers were able to target cancerous cells without affecting nontumor cells in the brain or in other organs. The team successfully demonstrated that CLTX-directed CAR T cells were highly effective at selectively killing human GBM cells in cell-based assays and in animal models without off-tumor targeting and toxicity. After great success in the laboratory, the City of Hope research team is excited to proceed with the first-in-human clinical trial using the CLTX-CAR T cells.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.